Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

被引:92
|
作者
Houghton, Peter J.
Morton, Christopher L.
Kolb, E. Anders
Lock, Richard
Carol, Hernan
Reynolds, C. Patrick
Keshelava, Nino
Maris, John M.
Keir, Stephen T.
Wu, Jianrong
Smith, Malcolm A.
机构
[1] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA
[2] Childrens Hosp Montefiore, Bronx, NY USA
[3] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia
[4] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[5] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA
[6] Abramson Family Canc Res Inst, Philadelphia, PA USA
[7] Duke Univ, Med Ctr, Durham, NC USA
[8] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
关键词
bortezomib; developmental therapeutics; preclinical testing;
D O I
10.1002/pbc.21214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Bortezomib is a proteasome inhibitor that has been approved by FDA for the treatment of multiple myeloma and that has completed phase 1 testing in children. The purpose of the current study was to evaluate the antitumor activity of bortezomib against the in vitro and in vivo childhood cancer preclinical models of the Pediatric Preclinical Testing Program (PPTP). Procedures. Bortezomib was tested against the PPTP in vitro panel at concentrations ranging from 0.1 nM to 1.0 mu M and was tested in vivo at a dose of 1 mg/kg for a planned duration of 6 weeks. Results. Bortezomib was uniformly active against the PPTP's in vitro panel, with a median IC50 of 23 nM and with a steep dose-response curve. The four acute lymphoblastic leukemia (ALL) cell lines had significantly lower IC50 values compared to the remaining lines of the in vitro panel. Limited in vivo activity was observed for bortezomib against the solid tumor xenografts tested, with one line meeting criteria for intermediate activity for the time to event measure and with the remaining lines showing low activity for this measure. Bortezomib demonstrated in vivo activity against the ALL panel, inducing two complete and two partial responses among seven evaluable lines. Conclusions. Administered at its MTD in mice, bortezomib demonstrated activity against selected lines of the PPTP's ALL in vivo panel. Further studies are indicated to determine the activity of bortezomib when combined with standard agents to treat childhood ALL.
引用
收藏
页码:37 / 45
页数:9
相关论文
共 50 条
  • [1] Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
    Houghton, Peter J.
    Morton, Christopher L.
    Kolb, E. Anders
    Gorlick, Richard
    Lock, Richard
    Carol, Hernan
    Reynolds, C. Patrick
    Maris, John M.
    Keir, Stephen T.
    Billups, Catherine A.
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2008, 50 (04) : 799 - 805
  • [2] Initial Testing (Stage 1) of the Topoisomerase II Inhibitor Pixantrone, by the Pediatric Preclinical Testing Program
    Kurmasheva, Raushan T.
    Reynolds, C. Patrick
    Kang, Min H.
    Allievi, Cecilia
    Houghton, Peter J.
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2014, 61 (05) : 922 - 924
  • [3] Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
    Maris, John M.
    Courtright, Joshua
    Houghton, Peter J.
    Morton, Christopher L.
    Kolb, E. Anders
    Lock, Richard
    Tajbakhsh, Mayamin
    Reynolds, C. Patrick
    Keir, Stephen T.
    Wu, Jianrong
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2008, 51 (01) : 42 - 48
  • [4] Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program
    Keir, Stephen T.
    Maris, John M.
    Reynolds, C. Patrick
    Kang, Min H.
    Kolb, E. Anders
    Gorlick, Richard
    Lock, Richard
    Carol, Hernan
    Morton, Christopher L.
    Wu, Jianrong
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2013, 60 (05) : 783 - 790
  • [5] Initial Testing (Stage 1) of Lapatinib by the Pediatric Preclinical Testing Program
    Gorlick, Richard
    Kolb, E. Anders
    Houghton, Peter J.
    Morton, Christopher L.
    Phelps, Doris
    Schaiquevich, Paula
    Stewart, Clinton
    Keir, Stephen T.
    Lock, Richard
    Carol, Hernan
    Reynolds, C. Patrick
    Maris, John M.
    Wu, Jianrong
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2009, 53 (04) : 594 - 598
  • [6] Initial Testing (Stage 1) of the Kinesin Spindle Protein Inhibitor Ispinesib by the Pediatric Preclinical Testing Program
    Carol, Hernan
    Lock, Richard
    Houghton, Peter J.
    Morton, Christopher L.
    Kolb, E. Anders
    Gorlick, Richard
    Reynolds, C. Patrick
    Maris, John M.
    Keir, Stephen T.
    Billups, Catherine A.
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2009, 53 (07) : 1255 - 1263
  • [7] Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program
    Lock, Richard B.
    Carol, Hernan
    Maris, John M.
    Kang, Min H.
    Reynolds, C. Patrick
    Kolb, E. Anders
    Gorlick, Richard
    Keir, Stephen T.
    Billups, Catherine A.
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2013, 60 (07) : E42 - E45
  • [8] Initial Testing (Stage 1) of the Akt Inhibitor GSK690693 by the Pediatric Preclinical Testing Program
    Carol, Hernan
    Morton, Christopher L.
    Gorlick, Richard
    Kolb, E. Anders
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Maris, John M.
    Billups, Catherine
    Smith, Malcolm A.
    Houghton, Peter J.
    Lock, Richard B.
    [J]. PEDIATRIC BLOOD & CANCER, 2010, 55 (07) : 1329 - 1337
  • [9] Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program
    Carol, Hernan
    Maris, John M.
    Kang, Min H.
    Reynolds, C. Patrick
    Kolb, E. Anders
    Gorlick, Richard
    Keir, Stephen T.
    Wu, Jianrong
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    Lock, Richard B.
    [J]. PEDIATRIC BLOOD & CANCER, 2014, 61 (08) : 1493 - 1496
  • [10] Initial Testing (Stage 1) of Vorinostat (SAHA) by the Pediatric Preclinical Testing Program
    Keshelava, Nino
    Houghton, Peter J.
    Morton, Christopher L.
    Lock, Richard B.
    Carol, Hernan
    Keir, Stephen T.
    Maris, John M.
    Reynolds, C. Patrick
    Gorlick, Richard
    Kolb, E. Anders
    Wu, Jianrong
    Smith, Malcolm A.
    [J]. PEDIATRIC BLOOD & CANCER, 2009, 53 (03) : 505 - 508